Effect of psychiatric severity on the outcome of methadone maintenance treatment

European Addiction Research

Volumn 17, Issue 2, 2011, Pages 80-89

  Pani, Pier Paolo ^a,b   Maremmani, Icro ^c,d,f   Pacini, Matteo ^d   Lamanna, Francesco ^c,e   Maremmani, Angelo G I ^c   Dell'Osso, Liliana ^c  

^a Società Italiana Tossicodipendenze   (Italy)

^b Territorial Department of Nephrology and Dialysis   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d G De Lisio Institute of Behavioral Sciences   (Italy)

^e AUSL 5   (Italy)

^f AU CNS   (Italy)

Author keywords

Addiction psychiatry; Comorbidity; Methadone maintenance; Opioids; Treatment outcome

Indexed keywords

METHADONE;

ADULT; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METHADONE TREATMENT; OPIATE ADDICTION; PRIORITY JOURNAL; SCORING SYSTEM; SUBSTANCE ABUSE; URINALYSIS;

ADULT; COCAINE; COHORT STUDIES; FEMALE; HEROIN; HUMANS; MALE; MENTAL DISORDERS; METHADONE; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; PATIENT COMPLIANCE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 78650246468     PISSN: 10226877     EISSN: None     Source Type: Journal    
DOI: 10.1159/000321465     Document Type: Article

References (67)

1. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, Goodwin FK: Comorbidity of mental disorders with alcohol and other drug abuse: resu lts from the Epidemiologic Catchment Area (ECA) Study. J Am Med Assoc 1990;264:2511-2518.
2. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler KS: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19. (Pubitemid 24028993)
3. Kessler RC, Nelson CB, McGonagle KA, Edlund MJ, Frank RG, Leaf PJ: The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization. Am J Orthopsychiatr 1996;66:17-31. (Pubitemid 26031236)
4. Grella CE, Karno MP, Warda US, Niv N, Moore AA: Gender and comorbidity among individuals with opioid use disorders in the NESA RC study. Addict Behav 2009;34:498-504.
5. Brooner RK, King VL, Kidorf M, Schmidt CW Jr, Bigelow GE: Psychiatric and substance use comorbidity among treatmentseeking opioid abusers. Arch Gen Psychiatry 1997;54:71-80. (Pubitemid 27044701)
6. Callaly T, Trauer T, Munro L, Whelan G: Prevalence of psychiatric disorder in a methadone maintenance population. Aust NZ J Psychiatry 2001;35:601-605. (Pubitemid 32982608)
7. Ross J, Teesson M, Darke S, Lynskey M, Ali R, Ritter A, Cooke R: The characteristics of heroin users entering treatment: findings from the Australian treatment outcome study (ATOS). Drug Alcohol Rev 2005;24:411-418. (Pubitemid 43024040)
8. Maremmani I, Pacini M, Lubrano S, Lovrecic M, Perugi G: Dual diagnosis heroin addicts. The clinical and therapeutic aspects. Heroin Add Rel Clin Probl 2003;5:7-98.
9. LaPorte DJ, McLellan AT, O'Brien CP, Marshall JR: Treatment response in psychiatrically impaired drug abusers. Compr Psychiatry 1981;22:411-419. (Pubitemid 11011536)
10. McLellan AT, Woody GE, Luborsky L, O'Brien CP, Druley KA: Increased effectiveness of substance abuse treatment: a prospective study of patient-treatment matching. J Ner v Ment Dis 1983;171:597-605. (Pubitemid 13017360)
11. McLellan AT, Luborsky L, Woody GE, Druley KA, O'Brien CP: Predicting response to alcohol and drug abuse treatments: role of psychiatric severity. Arch Gen Psychiatry 1983;40:620-625. (Pubitemid 13094929)
12. McLellan AT, Luborsky L, O'Brien CP: Alcohol and drug abuse treatment in three different populations: is there improvement and is it predictable? Am J Drug Alcohol Abuse 1986;12:101-120. (Pubitemid 16061498)
13. McLellan AT: 'Psychiatric severity' as a predictor of outcome from substance abuse treatments; in Meyer RE (ed): Psychopathology and Addictive Disorders. New York, Guilford Press, 1986, pp 97-139.
14. Rounsaville BJ, Kosten TR, Weissman MM, Kleber HD: Prognostic significance of psychopathology in treated opioid addicts: a 2.5-year follow-up study. Arch Gen Psychiatry 1986;43:739-745. (Pubitemid 16035158)
15. Rounsaville BJ, Kosten TR, Kleber HD: Long-term changes in current psychiatric diagnoses of treated opiate addicts. Compr Psychiatry 1986;27:480-498. (Pubitemid 16031004)
16. Rounsaville BJ, Tierney T, Crits-Christoph K, Weissman MM, Kleber HD: Predictors of outcome in treatment of opiate addicts: evidence for the multidimensional nature of addicts' problems. Compr Psychiatry 1982;23:462-478. (Pubitemid 13216263)
17. Woody GE, Luborsky L, McLellan AT, O'Brien CP, Beck AT, Blaine J, Herman I, Hole A: Psychotherapy for opiate addicts. Arch Gen Psychiatry 1983;40:636-645.
18. Woody GE, McLellan AT, Luborsky L, O'Brien CP, Blaine J, Fox S, Herman I, Beck AT: Severity of psychiatric symptoms as a predictor of benefits from psychotherapy: the Veterans Administration-Penn study. Am J Psychiatry 1984;141:1172-1177. (Pubitemid 14011486)
19. Cacciola SJ, Alterman AI, Rutherford MJ, McKay JR, Mulvaney FD: The relationship of psychiatric comorbidity to treatment outcomes in methadone maintained patients. Drug Alcohol Depend 2001;61:271-280. (Pubitemid 32119308)
20. Pani PP, Trogu E, Contu P, Agus A, Gessa GL: Psychiatric severity and treatment response in a comprehensive methadone maintenance treatment program. Drug Alcohol Depend 1997;48:119-126. (Pubitemid 27466472)
21. Maremmani I, Zolesi O, Aglietti M, Tagliamonte A, Shinderman M, Maxwell S: Methadone dose and retention during treatment of heroin addicts with Axis I psychiatriccomor bidity. J Addict Dis 2000;19:29-41. (Pubitemid 30659340)
22. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C, Bertacca S: Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 2004;75:37-45. (Pubitemid 38844575)
23. Gelkopf M, Weizman T, Melamed Y, Adelson M, Bleich A: Does psychiatric comorbidity affect drug abuse treatment outcome? A prospective assessment of drug abuse, treatment tenure and infectious diseases in an Israeli methadone maintenance clinic. Isr J Psychiatry Relat Sci 2006;43:126-136. (Pubitemid 44090655)
24. Maremmani I, Pacini M, Lubrano S, Perugi G, Tagliamonte A, Pani PP, Gerra G, Shinderman M: Long-term outcomes of treatment-resistantheroin addicts with and without DSM-IV axis I psychiatric comorbidity (dual diagnosis). Eur Addict Res 2008;14:134-142. (Pubitemid 351841865)
25. Maremmani I, Perugi G, Pacini M, Akiskal HS: Toward a unitary perspective on the bipolar spectrum and substance abuse: opiate addiction as a paradigm. J Affect Disord 2006;93:1-12. (Pubitemid 43833247)
26. Pani PP, Maremmani I, Trogu E, Gessa GL, Ruiz P, Akiskal HS: Delineating the psychic structure of substance abuse and addictions: should anxiety, mood and impulse-control dysregulation be included? J Affect Disord 2010;122:185-197.
27. Kranzler HR, Kadden RM, Burleson JA, Babor TF, Apter A, Rounsaville BJ: Validity of psychiatric diagnoses in patients with substance use disorders: is the interview more important than the interviewer? Compr Psychiatry 1995;36:278-288.
28. Nunes EV, Sullivan MA, Levin FR: Treatment of depression in patients with opiate dependence. Biol Psychiatry 2004;56:793-802. (Pubitemid 39539838)
29. Nunes EV, Rounsaville BJ: Comorbidity of substance use with depression and other mental disorders: from Diagnostic and Statistical Manual of Mental Disorders, ed 4 (DSM-IV) to DSM-V. Addiction 2006;101(suppl 1): 89):89):89-96.
30. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL: Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000;60:39-50. (Pubitemid 30255984)
31. Dean AJ, Bell J, Christie MJ, Mattick RP: Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatry 2004;19:510-513. (Pubitemid 39602776)
32. Gerra G, Fantoma A, Zaimovic A: Naltrexone and buprenorphine combination in the treatment of opioid dependence. J Psychopharmacol 2006;20:806-814. (Pubitemid 44622745)
33. Maremmani I, Pani PP, Pacini M, Perugi G: Substance use and quality of life over 12 months among buprenorphine maintenance-treated and methadone maintenancetreated heroin-addicted patients. J Subst Abuse Treat 2007;33:91-98. (Pubitemid 350198612)
34. Kastelic A, Dubajic G, Strbad E: Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction 2008;103:1837-1846.
35. Maremmani I, Pacini M, Pani PP, Perugi G, Deltito J, Akiskal H: The mental status of 1090 heroin addicts at entry into treatment: should depression be considered a 'dual diagnosis'? Ann Gen Psychiatry 2007;6:31.
36. Maremmani I, Pani PP, Pacini M, Bizzarri JV, Trogu E, Maremmani AGI, Gerra G, Perugi G, Dell'Osso L: Subtyping patients with heroin addiction at treatment entry: factor derived from the Self-Report Symptom Inventory (SCL-90). Ann Gen Psychiatry 2010;9:15.
37. Maremmani I, Castrogiovanni P: DAH-RS: Drug Addiction History Rating Scale. Pisa, University Press, 1989.
38. Derogatis LR: SCL-90: Administration, Scoring and Procedures Manual for the Revised Version. Baltimore, Clinical Psychometric Research, 1983.
39. Stata, release 10. College Station, StataCorp LP, 2007.
40. Verthein U, Degkwitz P, Haasen C, Krausz M: Significance of comorbidity for the longterm course of opiate dependence. Eur Addict Res 2005;11:15-21. (Pubitemid 40082206)
41. Wong DF, Wagner HN, Tune NE, Dannais RF, Pearlson GD, Links JM, Tamminga CA, Broussolle EP, Ravert HT, Wilson AA: Positron emission tomography reveals elevated D2 dopa mine receptors in drug naive schizophrenics. Science 1986;234:1558-1563. (Pubitemid 17125279)
42. Deutch AY: The regulation of subcortical dopamine system by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J Neural Transm 1992;36(suppl): 61-89.
43. Grace AA: Commentary. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41:1-24.
44. Kahn RS, Davis KL: New developments in dopamine and schizophrenia; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, pp 119-204.
45. Willner P: Dopaminergic mechanisms in depression and mania; in Bloom FE, Kupfer DJ (eds): Psychopharmacology: The Fourth Generation of Progress. New York, Raven Press, 1995, pp 921-931.
46. DiChiara G, Imperato A: Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA 1998;85:5274-5278.
47. DiChiara G, Imperato A: Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 1998;244:1067-1080.
48. Carlson ET, Simpson MM: Opium as a tranquilizer. Am J Psychiatry 1963:112-117.
49. Fink M, Simeon J, Itil TM, Freedman AM: Clinical antidepressant activity of cyclazocine: a narcotic antagonist. Clin Pharmacol Ther 1970;11:41-48.
50. Exstein I, Pickar D, Gold MS, Gold PW, Pottash ALC, Sweeney DR, Ross RJ, Rebard R, Martin D, Goodwin FK: Methadone and morphine in depression. Psychopharmacol Bull 1981;17:29-33. (Pubitemid 11180463)
51. Emrich HM, Vogt P, Herz A, Kissling W: An - tidepressant effects of buprenorphine. Lancet 1982;2:709.
52. Brizer DA, Hartman N, Sweeney J, Millman RB: Effect of methadone plus neuroleptics on treatment-resistant chronic paranoid schizophrenia. Am J Psychiatry 1985;142:1106-1107. (Pubitemid 16216097)
53. Feinberg DT, Hartman N: Methadone and schizophrenia. Am J Psychiatry 1991;148:1750-1751.
54. Bodkin JA, Zornberg GL, Lukas SE, Cole JO: Buprenorphine treatment of refractory depression. J Clin Psychopharmacol 1995;15:49-57.
55. Laqueille X, Baylé FJ, Spadone C, Jalfre V, Lôo H: Treatment of depressive syndromes in detoxified drug addicts: use of methadone. Biomed Pharmacother 1996;50:279-282. (Pubitemid 26330286)
56. Pani PP, Agus A, Gessa GL: Methadone as a mood stabilizer. Heroin Add Rel Clin Probl 1999;1:43-44.
57. Maremmani I, Zolesi O, Agueci T, Castrogiovanni P: Methadone doses and psychopathological symptoms during methadone maintenance. J Psychoactive Drugs 1993;25:253-263.
58. McLellan AT, Arndt IO, Metzger DS, Woody GE, O'Brien CP: The effects of psychosocial services in substance abuse treatment. J Am Med Assoc 1993;269:1953-1959. (Pubitemid 23106867)
59. McLellan AT, Alterman AI, Metzger DS, Grissom GR, Woody GE, Luborsky L, O'Brien CP: Similarity of outcome predictors across opiate, cocaine, and alcohol treatments: role of treatment services. J Consult Clin Psychol 1994;62:1141-1158. (Pubitemid 24377643)
60. O'Brien CP, Woody GE, McLellan AT: Enhancing the effectiveness of methadone using psychotherapeutic interventions; in Simon Onken L, Blaine JD, Boren JJ (eds): Integrating Behavioral Therapies with Medications in the Treatment of Drug Dependence, NIDA Res Monogr. Rockville, US Department of Health and Human Services, 1995, vol 150, pp 5-18.
61. Stitzer M, Petry N: Contingency management for treatment of substance abuse. Annu Rev Clin Psychol 2006;2:411-434. (Pubitemid 43799812)
62. Brooner RK, Kidorf M: Using behavioral reinforcement to improve methadone treatment participation. Sci Pract Perspect 2002;1:38-47.
63. Derogatis LR: Symptom Checklist-90-Revised; in Rush AJ (ed): Handbook of Psychiatric Measures. Washington, American Psychiatric Association, 2000, pp 81-84.
64. Schmitz N, Kruse J, Heckrath C, Alberti L, Tress W: Diagnosing mental disorders in primary care: the General Health Questionnaire (GHQ) and the Symptom Check List (SCL-90-R) as screening instruments. Soc Psychiatry Psychiatr Epidemiol 1999;34:360-366. (Pubitemid 29396513)
65. Holi MM, Marttunen M, Aalberg V: Comparison of the GHQ-36, the GHQ-12 and the SCL-90 as psychiatric screening instruments in the Finnish population. Nord J Psychiatry 2003;57:233-238. (Pubitemid 36805997)
66. Franken IH, Hendriks VM: Screening and diagnosis of anxiety and mood disorders in substance abuse patients. Am J Addict 2001;10:30-39. (Pubitemid 32201731)
67. Neufeld K, Kidorf M, King V, Stoller K, Clark M, Peirce J, Brooner RK: Using enhanced and integrated services to improve response to standard methadone treatment: changing the clinical infrastructure of treatment networks. J Subst Abuse Treat 2010;38:170-177.